Pharming Group (OTCMKTS:PHGUF) Sees Large Volume Increase – Should You Buy?

Pharming Group NV (OTCMKTS:PHGUF) saw unusually-high trading volume on Tuesday . Approximately 264,000 shares traded hands during mid-day trading, an increase of 3,499% from the previous session’s volume of 7,336 shares.The stock last traded at $1.20 and had previously closed at $1.28.

Pharming Group Stock Up 1.7%

The stock’s 50-day moving average price is $1.47 and its two-hundred day moving average price is $1.62. The stock has a market capitalization of $805.29 million, a PE ratio of 60.03 and a beta of 0.45. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.06 and a current ratio of 2.63.

Pharming Group (OTCMKTS:PHGUF) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.01) EPS for the quarter. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The firm had revenue of $72.45 million for the quarter, compared to analysts’ expectations of $92.06 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.